Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for
the treatment of hematological malignancies. However, in patients with solid tumors …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

The immunosuppressive tumor microenvironment (TME) represents a major barrier for
effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous …

The relevance of extracellular magnesium in cellular immunity remains largely unknown.
Here, we show that the co-stimulatory cell-surface molecule LFA-1 requires magnesium to …

Natural killer (NK) cells are a critical component of the innate immune system. Chimeric
antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to
augment their antitumour efficacy. The combined activating and co-stimulatory domains …

Chimeric antigen receptor (CAR)-T cell therapy has achieved successful outcomes against
hematological malignancies and provided a new impetus for treating solid tumors. However …

Chimeric antigen receptors (CAR) are engineered fusion proteins constructed from antigen
recognition, signaling, and costimulatory domains that can be expressed in cytotoxic T cells …